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Abstract: Platelet-rich plasma (PRP) associated with high molecular weight hyaluronic acid (HA) has
been clinically used for tissue regeneration in orthopedics. Despite the recognized beneficial clinical
outcomes (e.g., early pain control, improvement of patients’ functional limitation and longer-term
effectiveness compared to PRP and HA alone in mild and moderate osteoarthritis treatments), its use
is still challenging and controversial due to lack of standardization of association practical protocols.
Moreover, most studies neglect the matrix structure, that generates the ultimate properties of the
association among platelets, fibrin network and the microparticles. In the present work, we aimed to
analyze the influence of the PRP/HA association with a controlled matrix structure on the stability,
rheological behavior, release of growth factors and in vitro proliferation of human adipose-derived
mesenchymal cells (h-AdMSCs). The attenuation of the negative charge of HA was also evaluated.
Pure PRP (P-PRP) (i.e., plasma enriched with platelets and poor in leukocytes) was prepared by
centrifugation and activated with serum and calcium chloride (AP-PRP). Autocrosslinked hyaluronic
acid (AHA) was prepared by organocatalyzed auto-esterification and structured in microparticles
(MPAHA) by shearing. The attenuation of the negative charge of MPAHA was performed with chitosan
(CHT) by polyelectrolyte complexation yielding MPAHA-CHT. The results showed that microparticles
(MPs) have viscoelastic properties, extrusion force and swelling ratio appropriate for injectable
applications. The association of AP-PRP with the controlled structure of MPAHA and MPAHA-CHT
formed a matrix composed of platelets and of a fibrin network with fibers around 160 nm located
preferably on the surface of the MPs with an average diameter of 250 µm. Moreover, AP-PRP/MPAHA
and AP-PRP/MPAHA-CHT associations were non-toxic and supported controlled growth factor
(PDGF-AB and TGF-β1) release and in vitro proliferation of h-AdMSC with a similar pattern to that
of AP-PRP alone. The best h-AdMSC proliferation was obtained with the AP-PRP/MPAHA-CHT75:25
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indicating that the charge attenuation improved the cell proliferation. Thus, the association of AP-PRP
with the controlled structure of HA can be a valuable approach for orthopedic applications.
Keywords: platelet-rich plasma; polyelectrolyte complexes; auto-crosslinked hyaluronic acid;
chitosan; cell proliferation
1. Introduction
Platelet-rich plasma (PRP) is a concentrate of platelets and other components of plasma, which has
been widely used in regenerative medicine [1–4]. The regenerative potential of PRP is based on
the release of growth factors that occurs with platelet degranulation. The activation of PRP with
autologous serum and CaCl2 promotes the release of growth factors, which stimulate cell proliferation
and differentiation.
More recently, PRP has been associated with high molecular weight hyaluronic acid (HA), mainly
for orthopedic therapies [2,5]. HA is a glycosaminoglycan formed by a variable number of repeating
units of D-glucuronic acid and N-acetylglucosamine. Besides its role in lubrication and joints protection
against shocks, HA exhibits anti-inflammatory effects, relieves pain, provides signalization of specific
receptors (such as CD44), activates intrinsic repair processes of the cartilage, and normalizes the
endogenous production of HA [2,5–7].
Although several clinical reports have shown that the association of PRP and HA promotes tissue
regeneration, improves the mobility of patients, relieves pain and reduces the risk of infection in
orthopedics treatment, studies demonstrating its effectiveness are still limited and controversial [8,9].
Most studies report the use of growth factors and cytokines from PRP only, without considering the
fibrin network and its interactions with biomaterials as scaffolds. An ideal scaffold must provide a
frame for the cell attachment, proliferation and differentiation. The biomaterials should be non-toxic
and stable, having a pore size and/or porosity large enough to ensure cellular nutrition but not too large
to prevent cell migration. Furthermore, the surface topography and chemistry (wettability, softness,
stiffness, and roughness), microstructure (porosity, pore size, pore shape, and interconnectivity) and
mechanical properties have a significant influence on the processes involved in tissue regeneration [10].
Moreover, the standardization and optimization of this association (i.e., mass ratio PRP/HA),
molar mass of HA, need for crosslinking of HA, the structure of HA (hydrogel, micro or nanoparticles,
fibers), and protocols of mixture of PRP and HA, are still a challenge. Despite the numerous studies
described in the literature, as far as we know, there is only one study associating PRP/HA-based on a
matrix structure (Supplementary Figure S1) formed by platelets, fibrin network and/or uses crosslinked
HA microparticles [11].
Thus, this study, which also considers the structure of the matrix (platelets + fibrin network
+ microparticles), is the starting point to better understand the complex processes involved in this
association and in tissue healing. The crosslinking of HA prevents the rapid degradation of HA chains
by enzymatic action and/or by reactive oxidative species (ROS), and to extends the action over time.
Moreover, the crosslinking improves the mechanical properties, such as dumping and viscoelasticity
of HA, when compared to the non-crosslinked one.
The structuring of microparticles enables the increase of the surface area for cell spreading and
adhesion, contributing to the proliferation and control of matrix structure. Moreover, the reduction
of the negative charge by the addition of chitosan, improves cell adhesion on the microparticles,
while the fibrin network from activated PRP acts as the natural scaffold favoring the cell adhesion and
proliferation, and improving the mechanical properties and the stability of matrix (HA microparticles
+ fibrin network).
However, Shimojo et al. used 1,4-butanediol diglycidyl ether (BDDE) as crosslinkers [11]. Although
the association AP-PRP/HABDDE structured in microparticles has benefited the physicochemical and
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mechanical properties compared to FHA, the release of growth factors was similar to fibrin network
from AP-PRP and the mesenchymal cells proliferation (which are progenitors for bone and cartilage
mature cells contributing to bone and cartilage repair).
Our hypothesis is that a controlled matrix structure will increase the stability of association
P-PRP/HA preventing phase separation of free HA and will enable standardization of protocols
for clinical applications. Thus, the present work aimed to analyze the influence of the P-PRP/HA
association with controlled matrix structure on the stability, rheological behavior, delivery of growth
factors and in vitro proliferation of human-adipose mesenchymal cells (h-AdMSCs). The control
of matrix structure was obtained by association of fibrin network from activated P-PRP (AP-PRP)
with auto-crosslinked HA microparticles (MPAHA). Ren et al. [12] observed that HA may reduce cell
adhesion due to the negative charge of molecular chain, while Maroudas [13] demonstrated that it
is not the negative charge that impairs cell adhesion but its density. Thus, the effects of attenuation
of the negative charged HA by surfacing it with chitosan were also evaluated using the mass ratios
AHA/CHT 100/0 (very negative), 90/10 (neutral), 75/25 (positive), and 50/50 (very positive) [12,13].
The main advantage of auto-crosslinking, obtained by organocatalyzed auto-esterification, is to provide
stability to the HA matrix in the absence of chemical crosslinkers and to be used for different types of
micro/nanoparticles [14–23].
2. Materials and Methods
2.1. Materials
Hyaluronic acid (HA) in sodium salt form (Mw = 2 × 105 Da) was obtained from Spec-Chem Ind.
(Nanjing, China). Chitosan (Mw = 4 × 105 Da, degree of acetylation = 17.0 ± 0.7%) was purchased from
Polymar® (Fortaleza, CE, Brazil) and purified according to a protocol described by Nasti et al. [24].
Other chemicals were of reagent grade and were used without any further purification.
2.2. Methods
2.2.1. Preparation and Characterization of Auto-Crosslinked Hyaluronic Acid (AHA)
Initially, in order to prepare AHA, the intermediary tetrabutylammonium hyaluronate (HA-TBA)
was prepared. In brief, an aqueous solution of 0.5% (g/100 mL) sodium hyaluronate (Na-HA, pH 5.86)
was stirred in strongly acidic ion exchange resin Dowex® 50-8WX-400 mesh (Sigma-Aldrich, St. Louis,
MO, USA) for 8 h to form hyaluronic acid (H+-HA, pH ~3.80). The suspension was centrifuged
in a Rotina 380R centrifuge (Hettich® Zentrifugen, Tuttlingen, Germany) at 10,000 rpm for 10 min
to remove the resin, and it was then neutralized with tetrabutylammonium hydroxide (TBA-OH)
0.2 mol/L (Vetec®, Duque de Caxias, Rio de Janeiro, Brazil) to form the quaternary ammonium salt
of HA (TBA-HA, pH 6.96). The solution was then frozen and lyophilized in a Liobras L101 (Liobras,
São Carlos, SP, Brazil) for 48 h.
AHA was prepared by esterification reaction organocatalyzed with trimethylamine
(Supplementary Figure S2) according to the protocol described by Bellini et al. [25] and Schanté
et al. [26]. Briefly, HA-TBA (10 mEq of monomeric units) was solubilized in 50 mL of dimethyl sulfoxide
(DMSO) at 25 ◦C. Triethylamine (0.5 mEq) was added, and the resulting solution was stirred for 30 min.
A solution of 2-chloro-1-methyl pyridinium iodide (CMPI) (0.5 mEq) (Sigma-Aldrich, St. Louis, MO,
USA) in 15 mL of DMSO was slowly added dropwise over 1 h, and the mixture was kept at 30 ◦C for
15 h. A solution of sodium chloride 2.5% (g/100 mL) was then added, and the resulting mixture was
poured slowly into 150 mL of acetone, maintaining continuous stirring. The obtained precipitate was
centrifuged at 10,000 rpm for 10 min, washed thrice in 100 mL of 5:1 acetone: water and then thrice
with 100 mL of acetone, and vacuum-dried for 24 h at 30◦C.
Chemical characterization of AHA was performed by Fourier transform infrared (FTIR).
Measurements were performed in a Thermo Scientific Nicolet model 6700 (Thermo Scientific Nicolet™,
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Waltham, MA, USA), in the ATR mode with accessory SMART OMNI-SAMPLER, in the spectral range
of 4000–675 cm−1 with a resolution of 4 cm−1 over 64 scans.
2.2.2. Preparation and Characterization of Microparticles of AHA (MPAHA)
MPAHA microparticles were obtained by high shear homogenization in an Ultra-Turrax T25
homogenizer (IKA Labortechnik, Staufen, Germany) at 18,000 rpm for 20 min of plane hydrogel swelling
in ultrapure water. MPAHA were characterized by effective crosslink density Flory-Rehner calculations,
average diameter, degradation time, rheology, extrusion force, swelling ratio, and cytotoxicity.
Effective crosslink density Flory-Rehner calculations. Effective crosslink density was evaluated by
measuring the volumetric swelling and using a simplified version of the Flory and Rehner equation.
The value used for chitosan-water interaction parameter (χ) was 0.439 [27].
Degradation time. The gravimetric method described by Tang et al. [28] was used to estimate the
degradation time of the MPs through measurements of the remaining weight. The assay was carried
out with the MPs in phosphate buffer saline solution (PBS, pH 7.2) (LB Laborclin, Pinhais, PR, Brazil)
at 37 ◦C.
Average diameter. The average diameter of MPs was measured in water. The measurements were
performed with Malvern Mastersizer S laser diffraction (Malvern Instruments Ltd, Malvern, UK).
The standard deviation was calculated from ten consecutive measurements.
Rheology. Rheological measurements were performed in the oscillatory and steady regime at 25 ◦C
using a parallel plate geometry of 20 mm. Oscillatory measurements were conducted in the linear
region with a stress of 1.188 Pa and in the frequency range of 0.1 to 10 Hz. Steady shear measurements
were carried out at shear rates of 0.1–50 s−1. All rheological measurements were performed on a
rheometer Haake RheoStress 1 (Haake, Karlsruhe, Germany). The parameters were calculated from
the rheological curves, such as complex viscosity (G*), tan δ and power-law index (n) (Equations 1, 2,
and 3, respectively).
G∗ =
(
(G′)2 + (G′′ )2
)1/2
(1)
tan δ =
G′′
G′ (2)(
η = K γn−1
)
(3)
Extrusion force. The MPs were firstly loaded in 1-mL plastic syringes with 30-gauge needles.
Afterward, the force required to extrude was measured in an MTS 810 Servo-hydraulic Universal
Testing Machine (MTS Systems Corporation, Eden Prairie, MN, USA) (Load Cell 1.5 kN) at 25 ◦C at a
5.0 mm/min extrusion rate.
Swelling ratio. Swelling measurements of the MPs were performed in PBS at 37◦C for 72 h,
according to Shu et al. [29]. The swelling ratio (SR) was calculated using the following Equation 4.
SR =
Ws
Wd
(4)
where ws and wd are the weights of the scaffolds in the swelled state and the dry state, respectively.
Cytotoxicity. The cytotoxicity of the MPs expressed as the viability of h-AdMSCs cells
was carried out by exposing them to cell culture at 37 ◦C for 24 h (ISO 10993-5: "Tests for
Cytotoxicity—In Vitro Methods"). Then, cell viability was evaluated using the MTT assay
(3-[4,5-dimethyl-thiazol-2-yl]-2,5-diphenyltetrazolium bromide) (MTT, Sigma-Aldrich, St. Louis,
MO, USA), according to the modified Mosmann method [30].
2.2.3. Attenuation of Negative Charge of AHA
The attenuation of negative charges of AHA was performed by chitosan (CHT) addition.
Polyelectrolyte complexes of AHA-CHT (Supplementary Figure S3) were produced in pH 4.0 by
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complex coacervation between amino groups (NH3+) of CHT (pKb ~ 6.5) and carboxylic groups (COO−)
of AHA (pKa ~ 2.9) [31]. Briefly, AHA powder was swollen with a solution of CHT diluted acetic
acid 1% (g/100 mL) using a final polymer concentration of 1% (w/w). The reaction mixture at room
temperature was kept under stirring at 1,000 rpm overnight. Then, the formed precipitates were
washed with water and phosphate buffer saline (PBS) to pH 7 (pH 6.6–6.8). The mass ratio AHA:CHT
used in the microparticles were 90:10 (AHA-CHT90:10 – R+/- = 0.9, neutral), 75:25 (AHA-CHT75:25 – R+/-
= 2.8, positive), and 50:50 (AHA-CHT50:50 – R+/- = 8.3, very positive). The charge ratios (R+/-) were
estimated using the mass ratios AHA-CHT of MPs according to modified model by Rädler et al. [32].
Chemical characterization of AHA-CHT was performed by FTIR as described in Section 2.2.1.
2.2.4. Preparation and Characterization of Microparticles of AHA-CHT (MPAHA-CHT)
MPAHA-CHT in different mass ratios were obtained by high-speed shearing in an Ultra-Turrax
T25 homogenizer (IKA Labortechnik, Staufen, Germany) at 18,000 rpm for 20 min of plane hydrogel
swelling in ultrapure water. MPAHA-CHT were characterized as described in Section 2.2.2.
2.2.5. Preparation and Characterization of Activated P-PRP
Plasma rich in platelets and poor in leukocytes (P-PRP) was prepared according to Perez et al. [33].
P-PRP was prepared from the whole blood (WB) of donors, who were healthy individuals aged
between 30 and 40 years old and previously assessed through clinical examination. Human adipose
tissue-derived mesenchymal stem cells (h-AdMSCs) were provided by the Umbilical Cord Blood Bank
of Haematology and Hemotherapy Center of the University of Campinas. This research was approved
by the Ethics Committee of the Medical Sciences School of the University of Campinas (UNICAMP,
CAAE: 0972.0.146.000-11).
Briefly, whole blood (WB) was collected into 3.5 mL vacuum tubes (Vacuette®, Greiner Bio-One,
Americana, SP, Brazil) containing sodium citrate 3.2% (g/100 mL) as an anticoagulant. WB was firstly
centrifuged in a Rotina 380R centrifuge (Hettich® Zentrifugen, Tuttlingen, Germany) at 100× g for
10 min at 25◦C and the upper layer was collected to obtain P-PRP [33]. The concentrations of platelets in
WB (215.625 ± 7.028 pq/mm3) and in P-PRP were determined using the ABX Micros ES 60 hematology
analyzer (HORIBA ABX Diagnostics, Montpellier, France). P-PRP was obtained with approximately
twice the platelet concentration (495.000 ± 18.810 pq/mm3).
The activation of P-PRP was done with serum-containing thrombin and CaCl2 solution
(10% g/100 mL) as agonists applying the following conditions: agonist/P-PRP 20% (mL/100 mL),
Serum/CaCl2 volumetric ratio 9. These proportions provide fibrin network architecture with thin
fibers (approximately 160 nm average radius), which favors the proliferation of h-AdMSCs due to
its paracrine nature. Serum was prepared by collecting 5 mL of WB in tubes without anticoagulant.
After waiting 30 min to allow clot formation, WB was centrifuged at 2000× g for 10 min. The preparation
and activation protocols followed Perez et al. [33,34].
2.2.6. Association between AP-PRP and MPAHA
MPs were sterilized by steam in the autoclave at 126 ◦C (1.5 kgf/cm2) for 5 min. Then, the association
between AP-PRP and MPAHA (and MPAHA-CHT) was performed in laminar flow cabinet by adding
freshly activated P-PRP to MPs, in a volume/mass ratio AP-PRP:MP of 200 µL:200 mg. The components
were mixed with the tip of a pipette for a short time in 48-well microplates and kept for 45 min for gel
structuring. DMEM-LG (Gibco, Grand Island, NY, USA) was then added to the wells for cell culture.
AP-PRP/MPAHA and AP-PRP/MPAHA-CHT were characterized by the release of growth factors,
culture of seeded h-AdMSCs and images of the structured gel.
Release of growth factors. The release of platelet-derived growth factor AB (PDGF-AB) and
transforming growth factor β1 (TGF-β1) was performed after 45 min of gelation of AP-PRP alone,
AP-PRP/MPAHA and AP-PRP/MPAHA-CHT in the presence of the Dulbecco′s Modified Eagle′s Medium
with a low glucose concentration (DMEM-LG, Gibco, Grand Island, NY, USA) in 48-well microplates.
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The microplates were kept in an incubator with 5% CO2 over the assays. After sampling, the volume
was replaced with fresh medium at 3, 6, 12, 48, and 72 h without removing the gels from the wells.
The samples were stored at −80◦C until all have been collected. The concentrations of the released GFs
were measured using enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems, Minneapolis,
MN, USA), according to the manufacturer′s instructions and specifications.
Culture of seeded h-AdMSCs. The pre-cultured h-AdMSCs were trypsinized and resuspended in
P-PRP to a final cell concentration of 1 × 104 cells/mL. P-PRP containing h-AdMSCs was activated
and immediately added to MPAHA or MPAHA-CHT in 48-well microplates. The association with
seeded h-AdMSCs was kept at room temperature for 45 min for consolidation of the structure. After
that, DMEM was added. The cultivation of h-AdMSCs was carried out in 48-well tissue culture
plates by adding 1 mL of the culture medium DMEM-LG to the wells. The assays were done in
quadruplicate. The culture was maintained at 37 ◦C over 10 days. Cultivations in AP-PRP alone were
used as control. Cell proliferation was quantified by MTT assay. At 2, 4, 7, and 10 days of cultivation,
the samples were removed and transferred to 24-well plates. MTT (1 mL of 1 mg/mL) was then added,
and the cultivation proceeded at 37 ◦C for 4 h. The MTT solution was then discarded, and 1 mL of
dimethylsulfoxide (DMSO) was added to dissolve the purple formazan crystals. The samples were
shaken at 120 rpm for 30 min to ensure the homogeneous dissolution of the formazan dye, and 200 µL
of each sample was then transferred to a 96-well plate. The optical density was measured at 595 nm
using a microplate reader (FilterMax F5 Molecular Devices, Sunnyvale CA, USA). The cell number
in each well was quantified by a calibration curve of absorbance measured at 595 nm and the cell
concentration previously constructed.
Images of the structured gel. Images of the gel structures were obtained by scanning electron
microscopy (SEM) 4 days after h-AdMSC cultivation. The samples were fixed in a solution of
paraformaldehyde/glutaraldehyde for 2 h and then dehydrated in an ethanol series for 15-min intervals.
The samples were dried in a critical point dryer BAL-TEC CPD 030 (BAL-TEC®, Schalksmühle,
Germany). After gold coating in a Sputter Coater POLARON, SC7620 (VG Microtech, Ringmer, UK), the
samples were visualized in a scanning electron microscope Leo440i (LEO Electron Microscopy/Oxford,
Cambridge, UK) with an accelerating voltage of 20 kV.
2.2.7. Statistical Analysis
Each experiment was carried out in triplicate unless otherwise specified. All results are presented
as the mean ± standard deviation (SD). The experimental data from all the studies were analyzed using
analysis of variance (ANOVA). Statistical significance was set to p-value ≤ 0.05.
3. Results and Discussion
3.1. Structural Modifications of HA
FTIR spectroscopy was used to confirm the formation of AHA and AHA-CHT. The spectrum of
AHA showed the characteristic bands of polysaccharides (Supplementary Figure S4) between 3600
and 2800 cm−1 attributed to O–H stretching vibration and between 3000 and 2800 cm−1 attributed to
the C–H stretching vibrations and bands of N–H stretching vibrations overlapped with the O–H bands,
as expected.
The crosslinking was characterized by a decrease in the peaks at the region of 1800–1700 cm−1,
which is attributed to the stretching vibration of C=O of carboxylic acyl groups (~1700 cm−1) and ester
groups (1780–1760 cm−1).
The attributions of the absorption bands of AHA-CHT were performed according to Coimbra
et al. [35]. The AHA-CHT spectrum showed a broad band between 1700 and 1500 cm−1 which was
attributed to overlapping of the carbonyl and amide vibrations. The peak at 1598 cm−1 assigned
to the anti-symmetrical stretching vibration of the carbonyl group of the carboxylate in the AHA
appears slightly shifted to the left in the AHA-CHT, indicating the ionic interactions between the
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carboxylate group of AHA and the NH3+ group of CHT. Moreover, in the AHA-CHT spectrum a
slight displacement of peaks was also observed, attributed to the symmetric stretch vibration of the
carboxylate group νs (COO−) of AHA from 1407 to 1413 cm−1.
Due to the overlapping, it is difficult to distinguish any sign between the asymmetric and
symmetric bending vibrations of the NH3+ between 1625–1560 and 1550–1505 cm−1, respectively [36].
The AHA-CHT spectrum also showed a ratio change in the peaks at 1037 and 1077 cm−1, and in the
peaks, 1374 cm−1 compared to CHT spectra. These changes also suggested the formation of AHA-CHT.
3.2. Physicochemical and Mechanical Properties of MPs (MPAHA and MPAHA-CHT)
The swelling ratio (SR), effective crosslink density (Ve), molar mass between crosslinks (Mc) and
average particle diameter were determined for MPs (MPAHA and MPAHA-CHT) and results are shown
in Table 1. The values of the swelling ratio (SR) in PBS at 37 ◦C (Table 1) indicate that MPs were
extremely hydrophilic, with the capacity to accommodate high amounts of saline solution in their
structure, regardless the mass ratio.
Cells generally show good spreading, proliferation and differentiation on hydrophilic surfaces.
Both HA and CHT have an abundant number of hydrophilic groups, such as hydroxyl, amino, and
carboxyl groups, which promote water uptake in their structure. The addition of CHT significantly
affected (* p < 0.05) the swelling properties compared to MPAHA due to the decrease of hydrophilic
groups that make hydrogen bonds with water, confirming the ionic crosslinking. Moreover, SR of
MPAHA-CHT90:10 was significantly higher than other mass ratios indicating the lowest crosslinking
degree, as expected.
Flory & Rehner equations were used to determine the effective crosslinking density (Ve) and the
average molecular weight between crosslinks (Mc) which influence mainly the swelling, mechanical,
rheological properties and the stability of hydrogels. The addition of CHT increased Ve, as expected.
Moreover, we observed lower Mc values, indicating higher entanglement of chains.
Particle sizes of MPAHA-CHT were higher than MPAHA, indicating that the coverage with chitosan
attenuates the negative charge of the microparticles modifying the AHA surface. Nevertheless, MPs
kept mean diameters in the range of 190 to 280 µm, which are within the limits for injectable application
(<700 µm) [37].
The stability results (Figure 1a), expressed as weight loss in PBS at 37 ◦C, demonstrate that the
addition of CHT increased the stability of the MPs. MPAHA-CHT50:50 shows 14% of weight loss while
MPAHA shows 34%, confirming the physical crosslinking.
Moreover, except for the MPAHA-CHT90:10, the other MPAHA-CHT were stable (weight loss <
20%) over the 14 days of the assay, showing a capacity to absorb large quantities of PBS without
undergoing dissolution.
Table 1. Physicochemical and mechanical properties of the microparticles.
Physicochemical Properties
Microparticles Swelling RatioSR = Ws/Wd Ve Mc
Particle Size
(µm)
Weight Loss
in 24 h (%)
MPAHA 61 ± 8 1.28 × 10−6 1,015,979 190 ± 6 34 ± 6
MPAHA-CHT90:10 47 ± 1 2.79 × 10−5 155,067 273 ± 4 46 ± 3
MPAHA-CHT75:25 38 ± 2 3.72 × 10−5 116,635 280 ± 4 18 ± 7
MPAHA-CHT50:50 35 ± 1 4.18 × 10−5 103,614 263 ± 4 14 ± 3
Mechanical Properties
Microparticles G’ (Pa) G” (Pa) G* (Pa) tan δ (=G”/G’)in 1 Hz
n
η = K·γn−1
Extrusion
Force (N)
MPAHA 335.8 63.8 341.8 0.19 0.39 20 ± 1
MPAHA-CHT90:10 954.1 156.4 966.8 0.16 0.24 14 ± 2
MPAHA-CHT75:25 3211 436.4 3240.5 0.14 0.27 19.9 ± 0.6
MPAHA-CHT50:50 4933 560.2 4964.7 0.11 0.32 26.7 ± 0.4
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As seen in Figure 1a, the MPs lost most of their weight on the first day of the assay due to the
dissolution of weak bonds between the biopolymer chains. After this first stage, it seems that the
remaining biopolymers chains were highly bound together with innumerous ionic interactions and,
possibly, other forces like hydrophobic and hydrogen bonds.
The degradation rate was decreased by the addition of CHT, while the MPAHA-CHT90:10 showed
a similar degradation profile of MPAHA.
Figure 1b shows the results of cytotoxicity as assayed by MTT. The MPs were shown not to be
toxic against h-AdMSC, compared to positive toxicity controls (PTC = DMEM with phenol 0.5%).
Instead, the cells proliferated in the presence of the MPs. The effects of surface charge in MPs were
clear. The CHT coverage attenuated the negative charge at the proportions 90:10 and 75:25, but the
excess of positive charge in 50:50 also decreased cell proliferation.
The extrusion force increased with chitosan concentration reaching a maximum at the
MPAHA-CHT50:50 proportion as a consequence of the highest crosslinking degree.
The rheological behavior of the MPAHA and MPAHA-CHT determined by oscillatory and steady
measurements are shown in Figure 2a,b, respectively. MPs exhibited the gel-like behavior, as analyzed
by the storage (G’) and loss moduli (G”), where G’ is higher than G” in all studied frequency ranges
and the curves are parallel to the frequency axis. The addition of CHT increased the complex (G*),
elastic (G’), and viscous modulus (G”), revealing the crosslinking. The G* values indicate MPAHA
becomes more resistant to deformation and has a lower fluidity evidenced by tan δ values (damping)
with the addition of CHT. Moreover, MPAHA and MPAHA-CHT exhibited behavior typical of so-called
weak gels with tan δ (G”/G’) > 0.1 (Table 1), regardless of their mass ratios.
Figure 1. (a) The weight loss of the microparticles (MPs) as a function of the time of degradation (T = 37 ◦C,
PBS pH = 7.4). () MPAHA, (N) MPAHA-CHT90:10, () MPAHA-CHT75:25, and () MPAHA-CHT50:50.
(b) Cytotoxicity expressed as viability of h-AdMSCs exposed to the MPs. Negative toxicity control
(NTC) = DMEM with 10% FBS (fetal bovine serum), positive toxicity control (PTC) = DMEM with
phenol 0.5%. Mean ± standard deviation n = 3. * The population means were significantly different
from the positive control at p < 0.05.
Regardless of the mass ratio, MPAHA-CHT showed G’ values larger than 700 Pa in 1 Hz, which
was outside the adequate range (100–700 Pa) for injectable applications. Therefore, MPAHA-CHT
should be dispersed in the fluid phase or have the crosslinking degree decreased to fit the required
range. The flow curve (Figure 2b) showed a shear-thinning behavior for MPAHA and MPAHA-CHT,
which was characteristic of pseudoplastic fluids regardless the mass ratio. Although the addition of
CHT increases the viscosity of MPAHA-CHT, as expected, in relation to MPAHA, the flow behavior
index η (η = K·γn−1) was not significantly affected (Table 1).
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Figure 2. Rheological behavior of MPAHA and MPAHA-CHT as a function of the mass ratio.
(a) Oscillation spectrum and (b) Flow curve. () MPAHA, (N) MPAHA-CHT90:10, () MPAHA-CHT75:25,
and () MPAHA-CHT50:50. G’ (closed symbol), G” (open symbol).
3.3. Rheological and Biological Properties of Associations AP-PRP/MPAHA and AP-PRP/MPAHA-CHT
Based on the mechanical properties of MPs (Table 1), the AP-PRP/MPAHA and AP-PRP/MPAHA-CHT
associations prepared in this work were formed in 200 µL of P-PRP and 200 mg of MPAHA or
MPAHA-CHT. The associations were characterized by rheological properties, release kinetic of PDGF-AB
and TGF-β1 and h-AdMSC proliferation. Table 2 summarizes the determined rheological properties of
AP-PRP/MPAHA and AP-PRP/MPAHA-CHT.
The interactions between AP-PRP and MPAHA and MPAHA-CHT were evidenced by the values
of the complex viscosity (G*), which were higher for the associations than those of AP-PRP even
with the dilution effect. The G* value indicated AP-PRP/MPAHA-CHT50:50 (G* 185.5 Pa) renders
the association more resistant to deformation due to the strong electrostatic interaction (physical
crosslinking). The values of tan δ of the associations prepared from AHA-CHT were lower than
AP-PRP/MPAHA and AP-PRP, but they were similar to each other.
Table 2. Mechanical properties of the associations AP-PRP/MPAHA and AP-PRP/MPAHA-CHT.
Microparticles G’ (Pa) G” (Pa) G* (Pa) tan δ (=G”/G’)in 1 Hz
n
η = K·γn−1
AP-PRP 20.17 6.94 21.3 0.34 0.1953
AP-PRP/MPAHA 45.03 12.54 46.7 0.28 0.2456
AP-PRP/MPAHA-CHT90:10 94.66 18.03 96.4 0.19 0.3381
AP-PRP/MPAHA-CHT75:25 142.8 26.1 145.2 0.18 0.2412
AP-PRP/MPAHA-CHT50:50 181.8 36.86 185.5 0.20 0.1173
The association with AP-PRP as the fluid phase in a 1:1 volumetric ratio AP-PRP/MPAHA-CHT
and MPAHA-CHT maintained the weak gel-type behavior (Figure 3a) and the pseudoplastic gel-type
behavior (Figure 3b) of the MPs and adequate rheological properties with a reduction in G’ in 1 Hz ≈
100 Pa as needed, fitting the requirements for injectable use. This volume/ weight ratio AP-PRP/MPAHA
and AP-PRP/MPAHA-CHT was kept for the biological assays.
The release kinetic of PDGF-AB and TGF-β1 from the AP-PRP, AP-PRP/MPAHA, and AP-PRP/MPAHA
-CHT in DMEM are shown in Figure 4a,b, respectively. The fibrin network from AP-PRP was used as a
control. In both cases, the profiles are characterized by a predominant diffusion mechanism.
Most of the GFs (~ 70%) from AP-PRP occurred after approximately 12 h, related to the maximum
release, which is in agreement with the degradation time of the scaffolds observed in Figure 1a.
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These values are in agreement with in vitro results reported by Tsay et al. [38], showing a burst release
of 80% of PDGF-AB and 82% of TGF-β1 after 24 h and a controlled release over the following 14 days.
The release of PDGF-AB from the AP-PRP/MPAHA and AP-PRP/MPAHA-CHT structures were
approximately 70% and from the AP-PRP was 83%, while the release of TGF-β1 from the AP-PRP,
AP-PRP/MPAHA and AP-PRP/MPAHA-CHT structures ranged from 58 to 70% in 12 h. Maximum
TGF-β1 release was not observed until 72 h were reached.
All AP-PRP/MPAHA-CHT slowed down the release of PDGF-AB compared to AP-PRP alone
(Figure 4a), whereas only AP-PRP/MPAHA-CHT90:10 showed the modified release of TGF-β1 (Figure 4b).
Considering the dilution effects, only AP-PRP/MPAHA showed lower concentration profiles,
releasing a smaller amount of growth factors compared to AP-PRP.
These differences in the release profiles were justified by different chemical interactions of the
growth factors with the matrix from the association and/or by its degradation. Due to growth factors
are generally alkaline proteins (isoelectric point > 7) at physiological pH, they will have a positive
charge that ionically interacts with acidic species [39]. Thus, the elevated density of negative charges
of AP-PRP/ MPAHA increased the magnitude of electrostatic interactions with the growth factors,
resulting in a more controlled release [40].
In contrast, the release from AP-PRP/ MPAHA-CHT was governed by the degradation rate because
the ionic crosslinking reduced the number of exposed negative charges, thereby compromising the
electrostatic interactions.
Figure 3. Rheological behavior of the AP-PRP/MPAHA and AP-PRP/MPAHA-CHT (200 µL of
AP-PRP:200 mg of MPAHA or MPAHA-CHT). (a) Oscillation spectrum and (b) Flow curve.
( ) AP-PRP, () AP-PRP/MPAHA, (N) AP-PRP/MPAHA-CHT90:10, () AP-PRP/MPAHA-CHT75:25, and
() AP-PRP/MPAHA-CHT50:50. G’ (closed symbol), G” (open symbol).
To evaluate cell proliferation, the purified population of h-AdMSC was firstly characterized by
immunophenotyping cell surface markers such as CD29+, CD73+, CD90+, CD105+, and HLA-ABC+ or
the absence of HLA-DR+, and CD34-, CD45- by flow cytometry (data not shown).
MTT assay quantified the proliferation of the h-AdMSCs in the associations AP-PRP/MPAHA and
AP-PRP/MPAHA-CHT. The cell proliferation, measured by absorbance at 540 nm, was proportional to
the cell concentration. AP-PRP was used as control.
Figure 5 shows the results of h-AdMSC cultivation on AP-PRP/MP and AP-PRP, and the
micrographs of Figure 6 show the structures after 4 days of cultivation in DMEM at 37 ◦C.
The cell number per well per platelet number determined after two days exceeded the number of
seeded cells (1.0 × 104 cells/well/platelet number) in all associations, meaning that the cells maintained
in the matrices retained their viability. The results also demonstrate that the associations provided
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favorable microenvironments to support the cultivation and proliferation of h-AdMSC in vitro cultures
because in all associations the cell viabilities were remarkable up to 10 days.
Figure 4. Growth factor release profile from AP-PRP/MPAHA and AP-PRP/MPAHA-CHT. (a) PDGF-AB
and (b) TGF-β1. (#) MPAHA, (N) MPAHA-CHT90:10, () MPAHA-CHT75:25, and () MPAHA-CHT50:50.
() AP-PRP activated with Ca+2/ serum was used as control. The concentration of platelets in AP-PRP
was 495,000 ± 18,810 pq/mm3.
Figure 5. The proliferation profiles of h-AdMSCs cultured in the associations and AP-PRP as a function of
time. AP-PRP was used as control. The concentration of platelets in AP-PRP was 495.000 ± 18.810 pq/mm3.
Except in AP-PRP/MPAHA and AP-PRP/MPAHA-CHT90:10, the proliferations were statistically
(*p < 0.05) similar to AP-PRP after 10 days of cultivation.
Although for AP-PRP/MPAHA, AP-PRP/MPAHA-CHT90:10, and AP-PRP/MPAHA-CHT75:25 the
cell number determined after two days (3.5 × 104 cells/ well/platelet number) exceeded the number
of seeded cells (~ 1 × 104 cells/well/platelet number), the data show a long adaptation phase, or lag
time with incipient proliferation up to seven days, which was attributed to the negative charge of the
associations. On the 10th day, we observed an abrupt cell growth for AP-PRP/MPAHA-CHT75:25 with
the cell number statistically (*p < 0.05) similar to AP-PRP.
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AP-PRP and AP-PRP/MPAHA-CHT50:50 showed an exponential growth after two days confirming
the influence of the negative charge attenuation on cell cultivation. These results suggest that
CHT coverage favored h-AdMSC proliferation and the negative charge attenuation reduced the
lag-phase time.
Figure 6. Scanning electron microscopic micrographs of (a) AP-PRP, (b) AP-PRP/ AP-PRP/MPAHA,
(c) AP-PRP/MPAHA-CHT90:10, (d) AP-PRP/MPAHA-CHT75:25, and (e) AP-PRP/MPAHA-CHT50:50 after
four days of cultivation of h-AdMSCs.
Figure 6b–e shows that the gel matrix structure provided by the associations was similar to that
of the fibrin network (AP-PRP) Figure 6a. The fibers were approximately 160 nm, and were located
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preferably on the surface of the MPs, providing a large area covered by cell adhesion and proliferation.
The porous structure of the MPs could not be observed because they collapsed under dehydration,
which was required to obtain the images. It also was observed that the cells were homogeneously
spread on the fibrin fibers in the associations and in AP-PRP.
4. Conclusions
In this work, we studied a matrix consisted of platelets, fibrin network (natural scaffold) and
HA crosslinked microparticles. We considered the stability, the rheological properties, the toxicity,
the superficial area and the superficial charge of the matrix as the critical properties for the ‘association’
to be successful. These properties were evaluated and the results showed that the matrix is promising
for orthopedic tissue engineering. The auto-crosslinked microparticles approach represents a strategy
for controlling the hyaluronic acid structure for association with P-PRP (pure PRP, i.e., plasma enriched
with platelets and poor in leukocytes). This approach is safe, allows easier protocol standardization and
may be useful for clinical applications. Moreover, the microparticles improved the physicochemical
and mechanical properties of activated P-PRP and provided a large surface area for cell adhesion
and proliferation. The association formed matrix (microparticles + fibrin network + platelets) with
the fibrin network preferentially on the surface of the microparticles. The coverage with chitosan
attenuated the negative charge of the microparticles, producing proliferation profiles similar to the
activated P-PRP alone (200 µL of AP-PRP) even with the dilution effects of 1:1 in the associations (200 µL
of AP-PRP:200 µg) of MPs. Therefore, the reduction of negative charge density of the microparticles
favored cell proliferation. The possibility to obtain injectable formulations opens perspectives on the use
of these biomaterials in non-surgical applications of regenerative medicine, especially in orthopedics.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/2073-4360/11/10/
1568/s1.
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